MDT-AP-0337
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 102.96000000000001
- os_event
- false
- age_years
- 17
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.881601167
- umap2_2d
- -0.002235054
- umap1_3d
- 0.486630387
- umap2_3d
- -3.421196749
- umap3_3d
- 0.03201809
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.250
- G2M_CHECKPOINT+0.140
- DNA_REPAIR+0.100
- SPERMATOGENESIS+0.100
- MYC_TARGETS_V1+0.090
- KRAS_SIGNALING_DN+0.040
- MITOTIC_SPINDLE+0.010
- PANCREAS_BETA_CELLS-0.010
- UNFOLDED_PROTEIN_RESPONSE-0.010
- NOTCH_SIGNALING-0.030
Top 10 suppressed
- ANGIOGENESIS-0.500
- INFLAMMATORY_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.410
- COMPLEMENT-0.380
- INTERFERON_ALPHA_RESPONSE-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
- TNFA_SIGNALING_VIA_NFKB-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- KRAS_SIGNALING_UP-0.360
- CHOLESTEROL_HOMEOSTASIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2SFTWNVE | medulloblastoma | — | 0.914 |
| 2 | MDT-AP-1193 | Med | Medulloblastoma | 0.913 |
| 3 | SRR820468 | GTEX | — | 0.907 |
| 4 | SRR1441224 | GTEX | — | 0.903 |
| 5 | BS_VMEX27TN | medulloblastoma | — | 0.900 |
| 6 | BS_ERWT0ZWE | medulloblastoma | — | 0.899 |
| 7 | BS_QPPPGYP4 | medulloblastoma | — | 0.898 |
| 8 | SRR1322163 | GTEX | — | 0.897 |
| 9 | BS_HTEPAKCM | medulloblastoma | — | 0.896 |
| 10 | BS_61E80SD6 | medulloblastoma | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |